Solid Biosciences Inc. (SLDB)
$5.47-6.01%Close
SELLCRISIS · day 16
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $539M
- Beta
- 2.47
- P/E (TTM)
- -2.86
- Short % float
- 16.27%
- Days to cover
- 7.7
- SI change
- -25.6%
- 1W
- -20.15%
- 1M
- -34.65%
- vs SPY 1W
- -20.01%
- vs SPY 1M
- -37.15%
Industry peers
FMP comparable companies · ranked by market cap
- PTCTSELLPTC Therapeutics, Inc.$5.3BCRISISQ 18$62.92-0.42%
- EWTXSELLEdgewise Therapeutics, Inc.$4.1BCRISISQ 15$38.45+2.04%
- DYNSELLDyne Therapeutics, Inc.$3.0BCRISISQ 3$15.96-1.70%
- SRPTSELLSarepta Therapeutics, Inc.$1.8BCRISISQ 13$17.44+1.94%
- MGTXSELLMeiraGTx Holdings plc$961MCRISISQ 6$10.38-5.33%
- FDMTSELL4D Molecular Therapeutics, Inc.$680MCRISISQ 3$13.00-1.29%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on SLDB?
- LOPJLB’s latest quantitative signal on Solid Biosciences Inc. (SLDB) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is SLDB in?
- Solid Biosciences Inc. (SLDB) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Solid Biosciences Inc. (SLDB) do?
- Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, whi…